NICE says no to Avastin, but drug is already available through cancer drugs fund
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal institute for England and Wales, says it will not be recommending Roche's VEGF targeted anticancer Avastin (bevacizumab) for metastatic breast cancer because of its high cost and doubts over its benefits. Nevertheless, some patients in England already have access to the treatment through the cancer drugs fund.